HighVista Strategies’s Dianthus Therapeutics DNTH Stock Holding History

HighVista Strategies’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.98M	Buy	51,125 +15,538	+44%	+$1.36M	1.14%	25
2026 Q1	$2.99M	Sell	35,587 -12,897	-27%	-$747K	0.82%	37
2025 Q4	$2M	Sell	48,484 -5,741	-11%	-$223K	0.51%	52
2025 Q3	$2.13M	Buy	54,225 +38,364	+242%	+$980K	0.52%	58
2025 Q2	$295K	Sell	15,861 -15,526	-49%	-$291K	0.11%	138
2025 Q1	$569K	Hold	31,387	–	–	0.22%	121
2024 Q4	$684K	Buy	31,387 +11,579	+58%	+$298K	0.25%	116
2024 Q3	$542K	Buy	+19,808	New	+$552K	0.19%	124

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

HighVista Strategies's DNTH Position: Q2 2026 in Review

HighVista Strategies increased its Dianthus Therapeutics (DNTH) stake by 44% in Q2 2026, buying an estimated $1.36M and bringing the position to 51,125 shares worth $4.98M. The position accounts for 1.14% of the portfolio, ranked #25.

HighVista Strategies first reported a position in DNTH in Q3 2024 and has held it in 8 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

HighVista Strategies held 51,125 shares of Dianthus Therapeutics worth $4.98M as of Q2 2026.
HighVista Strategies bought 15,538 Dianthus Therapeutics shares in Q2 2026, an estimated $1.36M.
Dianthus Therapeutics made up 1.14% of HighVista Strategies's portfolio in Q2 2026, its #25 holding.
HighVista Strategies first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 8 quarters since.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.